Summary: Uninvestigated Failure Modes with Therapeutic Implications
Methodological caveat. The speculations developed throughout this chapter consistently propose vicious cycles, self-amplifying cascades, and multi-node feedback loops. This pattern warrants explicit acknowledgement: every proposed loop conveniently generates therapeutic targets, and alternative models in which the same observations arise from independent, non-interacting causes are systematically less developed. The reader should weight the cyclic framings as hypothesis-generating tools — useful for motivating specific experiments — rather than as established mechanisms. The directionality of the speculations (toward complexity and toward treatment targets) reflects the author’s integrative framing; a reductionist framing that explains the same data through fewer, independent mechanisms deserves equal prior probability until differentiating experiments are performed.
The systematic analysis above identifies the following failure modes that are mechanistically established in other diseases, plausibly operative in ME/CFS based on upstream or downstream evidence, but have never been directly studied in ME/CFS patients:
- PDC cofactor depletion (thiamine, riboflavin, lipoic acid): each causes PDC failure in isolation; combination deficiency is untrialled
- KGDHC failure: same cofactors as PDC; simultaneous impairment is mechanistically expected but unmeasured
- ISCU (iron-sulfur cluster assembly): failure would cause combined aconitase, Complex I, Complex II, and ETF-QO deficiency simultaneously
- ANT autoantibodies: could produce cellular energy crisis with normal ETC oxygen consumption
- Cardiolipin oxidation: elamipretide intervention studied in Barth syndrome and Long COVID; not trialled in ME/CFS
- CPT1/malonyl-CoA regulation: the fatty acid–glucose utilization switch has not been characterized
- NRF2 pathway: master antioxidant regulator upstream of documented antioxidant deficits (MnSOD, GPX4, glutathione), though each target also has NRF2-independent regulation; directionality unknown (suppressed vs compensatorily upregulated but overwhelmed) — the measurement would resolve this and determine whether NRF2 activators are appropriate (Davis et al. 2025) (Morris et al. 2023)
- PRDX3 and thioredoxin: PRDX3-KO animal model is phenotypically similar to ME/CFS; not measured in patients
- PGC-1α post-translational inactivation: blocks both biogenesis and antioxidant recovery; PGC-1\(\alpha\) mRNA paradoxically upregulated in ME/CFS muscle (Wang et al. 2023), protein normal in PBMCs (Castro-Marrero et al. 2013), upstream AMPK signaling impaired (Brown et al. 2018) — the failure is likely post-translational (hyperacetylation), not transcriptional
- NAD+–sirtuin–acetylation hub: NAD+ depletion in energy-intensive tissues may simultaneously inactivate SIRT1 (blocking PGC-1\(\alpha\) and NRF2 deacetylation) and SIRT3 (impairing Complex I and IDH2), unifying gaps G22, G34, and G39 under a single upstream regulator (NAD+–Sirtuin–Acetylation Hub: Unified Upstream Regulator of G22, G34, and G39)
- UCP2/UCP3 upregulation: predicted compensatory response to ROS that would further reduce ATP yield; not measured in ME/CFS skeletal muscle
- Riboflavin (as standalone intervention): the FAD-dependent beta-oxidation/ETC failure signature has never been formally trialled
See Chapter Medications Targeting Underlying Mechanisms for treatment protocols related to established interventions (CoQ10, L-carnitine, NADH). The gaps listed above represent priority research directions rather than current clinical recommendations.